Text

Profile of Soluble Urokinase Plasminogen Activation Receptor (suPAR) Level in Tuberculosis Patients Serum (As Therapy Monitoring)

---

Dutch study shows that Upar expression content is significantly in tuberculosis patient’s psiphsy monosit compared to those in the healthy control. So far, there is biologic marker used which can accurately observe response improvement in the treatment of lung tuberculosis. The aim of this research is to investigate whether the serum level of soluble utokinase plasminogen activator (suPAR) carries information in monitoring TB treatment for lung Tuberculosis patients. suPAR was measured by ELISA in 21 individuals at the time of enrolment into observational cross sectional based on active tuberculosis and 5 individuals as healthy control. There were 3 groups, 1). Patients who had not started treatment (n=7), 2). Patients who had been treated for 2 months (n=7), 3). Patients who had been treated for 6 months (n=7). Among groups, there were no difference in mean of body mass index, erythrocyte sedimentation rate and monocyte count. Patients positive for TB on direct microscopy were 29% (6 from 21 patients), 2 patients each groups. The suPAR levels were elevated in patients with active TB compared to healthy control (p

---

Availability

No copy data

Detail Information

Series Title

-

Call Number

Jurnal Kedokteran Brawijaya, 24(1): 30-35

Publisher

Yogyakarta : Fk. Universitas Brawijaya., 2008

Collation

4p.

Language

ISBN/ISSN

0216-9347

Classification

-

Content Type

-

Media Type

-

Carrier Type

-

Edition

-

Subject(s)

TUBERCULOSIS
lung
RINARY PLASMONOGEN ACTIVATOR

Specific Detail Info

-

Statement of Responsibility

-

Other version/related

File Attachment

Comments

---

You must be logged in to post a comment